European Commission strikes deal with German biotech firm CureVac for potential COVID-19 vaccine
Updated: 2020-11-18 10:03:31 KST
The European Commission has struck a deal with German biotech firm CureVac to purchase up to 405 million doses of its potential COVID-19 vaccine.
The Commission's chief welcomed the agreement, and added that once the vaccines are found to be safe and effective, every member-state will receive the vaccines at the same time under the same conditions.
This is the fifth addition to the EU's COVID-19 vaccine portfolio with deals already in place with AstraZeneca, Sanofi and Johnson & Johnson.